Inspira Technologies OXY B.H.N. (NASDAQ:IINN) vs. Pacific Biosciences of California (NASDAQ:PACB) Head to Head Contrast

Inspira Technologies OXY B.H.N. (NASDAQ:IINN) and Pacific Biosciences of California (NASDAQ:PACB) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation and analyst recommendations.

Valuation & Earnings

This table compares Inspira Technologies OXY B.H.N. and Pacific Biosciences of California”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inspira Technologies OXY B.H.N.	$289,000.00	90.43	-$13.22 million	N/A	N/A
Pacific Biosciences of California	$160.03 million	2.37	-$546.38 million	($0.43)	-2.84

Inspira Technologies OXY B.H.N. has higher earnings, but lower revenue than Pacific Biosciences of California.

Profitability

This table compares Inspira Technologies OXY B.H.N. and Pacific Biosciences of California’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Inspira Technologies OXY B.H.N.	N/A	N/A	N/A
Pacific Biosciences of California	-80.35%	-571.06%	-18.82%

Institutional & Insider Ownership

12.7% of Inspira Technologies OXY B.H.N. shares are owned by institutional investors. 29.4% of Inspira Technologies OXY B.H.N. shares are owned by company insiders. Comparatively, 2.5% of Pacific Biosciences of California shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Inspira Technologies OXY B.H.N. and Pacific Biosciences of California, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inspira Technologies OXY B.H.N.	1	0	1	0	2.00
Pacific Biosciences of California	2	2	1	0	1.80

Inspira Technologies OXY B.H.N. presently has a consensus target price of $2.00, suggesting a potential upside of 175.10%. Pacific Biosciences of California has a consensus target price of $1.83, suggesting a potential upside of 50.27%. Given Inspira Technologies OXY B.H.N.’s stronger consensus rating and higher probable upside, equities analysts clearly believe Inspira Technologies OXY B.H.N. is more favorable than Pacific Biosciences of California.

Risk & Volatility

Inspira Technologies OXY B.H.N. has a beta of 2.16, indicating that its share price is 116% more volatile than the S&P 500. Comparatively, Pacific Biosciences of California has a beta of 2.4, indicating that its share price is 140% more volatile than the S&P 500.

Summary

Inspira Technologies OXY B.H.N. beats Pacific Biosciences of California on 9 of the 11 factors compared between the two stocks.

About Inspira Technologies OXY B.H.N.

Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation for the treatment of acute respiratory failure. Its lead product is the augmented respiration technology system, a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. Inspira Technologies Oxy B.H.N. Ltd. was incorporated in 2018 and is headquartered in Ra'annana, Israel.

About Pacific Biosciences of California

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.